THIRD ANNOUNCEMENT

Fragments 2024
9th RSC-BMCS Fragment-based Drug Discovery Meeting

3rd – 5th March, 2024
Hinxton Hall, Cambridge, UK

Image produced by Alison Woolford of Astex
Synopsis

The aim of the 9th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with this theme in having over three-quarters of the presentations focused on case studies. This will be complemented by technology progress in high concentration, NMR, SPR and X-ray screening.

Meet the Experts Session

On Sunday 3rd March there will be “Meet the Experts” interactive session and it is included in your delegate package. The Meet the Experts in Fragment-Based Drug Discovery (FBDD) is designed to provide participants with an understanding of the principles and applications of FBDD in drug discovery. The session leaders Anna Hirsch, Dan Erlanson, and David Rees will present and discuss FBDD’s approach that focuses on identifying small, low molecular weight fragments as starting points for drug design, leading to the discovery of launched drugs. The session will encourage questions and answers from the audience in an informal atmosphere. After the interactive session, a buffet dinner will be served in the Hinxton Hall conference centre.

Organising Committee

Emma Grant  
GSK

Gordon Saxty  
NS-MC Consulting LTD (Chair)

Mary Wheldon  
University of Dundee (Treasurer)

Iva Lukac  
Charnwood Discovery

Marianne Schimpl  
AstraZeneca

Alison Woolford  
Astex Pharmaceuticals

Secretariat contact:
Hg3 Conferences  
events@hg3.co.uk  
+44 (0) 1423 529333

To find out more, visit the BMCS website by using the URL or by scanning the QR code here:

https://www.rscbmcs.org/events/fragments24
9th RSC-BMCS Fragment-based Drug Discovery Meeting

Programme

Sunday 3rd March
15:00-  Meet the Experts session: with Anna Hirsch, Dan Erlanson, and David Rees
17:20  Buffet Dinner

Monday 4th March
09:00  Registration and Refreshments
10:20  Opening remarks
10:30  Leveraging fragment-based drug discovery (FBDD) to inform other screening platforms: How to describe, inventory, and incorporate fragment pharmacophores into picks from other platforms
      Justin Dietrich, Abbvie, US
11:00  Automation, automation: Application of automated synthesis to off-DNA PAC-FragmentDEL hits and crude reaction screens for rapid fragment elaboration
      Lucie Guetzoyan, Vernalis, UK
11:30  New Oncology targets from Fragment Leads
      John Spencer, University of Sussex, UK
12:00  Lunch, exhibition, posters (odd-numbers) and networking
12:30  Late Breaking Talk
13:30  An NMR Toolbox for Drug Design
      Gerald Platzer, University of Vienna, Austria
14:00  Current and emerging opportunities for fragment-based drug design assisted with molecular simulations
      Julien Michel, University of Edinburgh, UK
15:00  Refreshments, exhibition and networking
15:30  RSC-BMCS Hall of Fame Winner talk
      Andrew Hopkins, Excientia, UK
16:15  Pannel Discussion
17:15  Drinks Reception, exhibition, posters (even-numbers) and networking
19:00  Conference Dinner

Tuesday 5th March
09:00  Structure-based fragment merging and linking affording potent and selective inhibitors of Pseudomonas aeruginosa elastase LasB
      Anna Hirsch, Helmholtz Institute for Pharmaceutical Research Saarland, Germany
09:30  Discovery of inhibitors targeting wild-type and a drug-resistant mutant of c-MET
      Iacovos Michaelides and Gavin Collie, AstraZeneca, UK
10:00  Fragment Based Drug Discovery of Allosteric SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2) Inhibitors
      Nicola Wilsher, Astex, UK
10:30  Refreshments, exhibition and networking
11:00  Deconstruction of HTS hits into fragments as a route to discover potent BCL6 inhibitors and degraders
      Rob Van Monfort, Institute of Cancer Research, UK
11:30  Discovery of potent SOS1 inhibitors through complementary use of FBDD and HTS
      Martina Schaefer, Nuvisan, Germany
12:00  Lunch, exhibition, all posters and networking
12:30  Reversible Dual-Covalent Molecular Locking of the 14-3-3/ERRγ Protein–Protein Interaction as a Molecular Glue Drug Discovery Approach
      Peter Cossar, Eindhoven University of Technology, Netherlands
13:30  From fragment to allosteric activator – targeting a novel metabolic regulator using FBDD
      Matthew Calabrese, Pfizer, UK
14:00  Refreshments, exhibition and networking
15:00  Reactive fragments in Chemical Biology
      Jonathan Pettinger, GSK, UK
15:30  Covalent fragment-based drug discovery
      Dan Erlanson, Frontier Medicines, US
16:15  Closing Remarks